Microbot Medical Hires Alon Tamir to Capture 2.3M-Procedure EMEA Market Ahead of CE Mark
Microbot Medical appointed Alon Tamir as Vice President of Sales for Europe, Middle East and Asia to spearhead regulatory, distribution and partnership efforts ahead of a CE mark expected by end-2026. Europe’s peripheral endovascular market spans roughly 2.3 million annual procedures, following the U.S. full market release.
1. Appointment of EMEA Sales VP
Microbot Medical appointed Alon Tamir as Vice President of Sales for Europe, the Middle East and Asia, leveraging his over two decades of medical technology experience to lead go-to-market strategies, distribution networks and strategic partnerships across the region.
2. Commercial Readiness in EMEA
The company will build regulatory, operational and commercial core capabilities by applying the disciplined approach used in its U.S. launch, following completion of Limited Market Release and full market release phases in the United States.
3. Regulatory Timeline and Market Potential
The LIBERTY Endovascular Robotic System received FDA clearance in September 2025 and is on track for CE mark approval by end-2026; Europe alone accounts for approximately 2.3 million peripheral endovascular procedures annually, underscoring significant growth opportunity.